Literature DB >> 31643046

An Overview of the Current ADC Discovery Landscape.

L Nathan Tumey1,2.   

Abstract

The prototypical ADC mechanism involving antigen-mediated uptake and lysosomal release is both elegantly simple and scientifically compelling. However, recent clinical-stage failures have prompted a reevaluation of this delivery paradigm and have resulted in an array of new technologies that have the potential to improve the safety and efficacy of up and coming programs. These innovations can generally be categorized into seven areas that will be elaborated on in this chapter: (1) Exploiting new payload mechanisms; (2) Increasing the drug-antibody ratio (DAR); (3) Increasing the antibody penetration; (4) Overcoming ADC resistance mechanisms; (5) Increasing the efficiency of ADC uptake and processing; (6) Mitigating off-target payload exposure; and (7) Employment of noncytotoxic payloads. It is our belief that these seven areas capture the current "landscape" of innovations that are taking place in the design of next-generation ADCs. Together, these advancements are reshaping the ADC field and providing a path forward in the face of the recent clinical setbacks.

Keywords:  ADC; Conjugation; DAR; Payload; Resistance; Toxicity; Tumor penetration

Mesh:

Substances:

Year:  2020        PMID: 31643046     DOI: 10.1007/978-1-4939-9929-3_1

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  3 in total

Review 1.  Antibody drug conjugate: the "biological missile" for targeted cancer therapy.

Authors:  Zhiwen Fu; Shijun Li; Sifei Han; Chen Shi; Yu Zhang
Journal:  Signal Transduct Target Ther       Date:  2022-03-22

Review 2.  Recent advances in the translation of drug metabolism and pharmacokinetics science for drug discovery and development.

Authors:  Yurong Lai; Xiaoyan Chu; Li Di; Wei Gao; Yingying Guo; Xingrong Liu; Chuang Lu; Jialin Mao; Hong Shen; Huaping Tang; Cindy Q Xia; Lei Zhang; Xinxin Ding
Journal:  Acta Pharm Sin B       Date:  2022-03-17       Impact factor: 14.903

3.  Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin.

Authors:  Carissa E Chu; Jonathan Chou; Martin Sjöström; Emily A Egusa; Ewan A Gibb; Michelle L Badura; Jun Zhu; Vadim S Koshkin; Bradley A Stohr; Maxwell V Meng; Raj S Pruthi; Terence W Friedlander; Yair Lotan; Peter C Black; Sima P Porten; Felix Y Feng
Journal:  Clin Cancer Res       Date:  2021-06-09       Impact factor: 12.531

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.